Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 11/20 | 0.50 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26630437 | 0.86 | RORC (0.54) | RORCEGFRGSK3BSCN5ASCN9A | |
| SCHEMBL26630298 | 0.79 | RORC (0.47) | RORCGSK3B | |
| SCHEMBL26630389 | 0.78 | RORC (0.46) | RORCEGFRGSK3BBRD4 | |
| SCHEMBL26630243 | 0.71 | EGFR (0.44) | RORCEGFRSCN5ASCN9A | |
| SCHEMBL26630296 | 0.70 | EGFR (0.45) | RORCEGFRGSK3BBRD4NOX1 | |
| SCHEMBL26630303 | 0.70 | EGFR (0.45) | RORCEGFRGSK3BBRD4NOX1 | |
| SCHEMBL26630202 | 0.67 | GSK3B (0.46) | EGFRGSK3BBRD4 | |
| SCHEMBL28016710 | 0.65 | EGFR (0.56) | EGFRBRD4RAB9A | |
| SCHEMBL17316734 | 0.64 | KDM4E (0.54) | RORCSCN5ASCN9A | |
| SCHEMBL15807915 | 0.64 | TGM2 (0.58) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2025-09-11 | — | — | US | disclosed |
| EP-4514780-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | Dong-A ST Co., Ltd. (KR) | 2025-03-05 | — | — | EP | disclosed |
| WO-2023209651-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | DONG-A ST CO., LTD. (KR) | 2023-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282735-A1 | BICYCLE COMPOUNDS AS TEAD INHIBITOR | TEAD1, TEAD2, TEAD3 | RORC 239/4885EGFR 3961/4885GSK3B 245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.